Pacific Biosciences Reports $37.2 Million Revenue in Q1 2026, Significant Loss Reduction

Pacific Biosciences of California, Inc. (PacBio) reported its financial results for the first quarter of 2026, revealing total revenue of $37.2 million, a slight increase from $37.2 million in the same period of 2025. The revenue breakdown included $31.5 million from product sales, which saw a marginal increase of 1% year-over-year, and $5.6 million from service and other revenue, which decreased by 7%. The company achieved a gross profit of $12.8 million, a significant turnaround from a gross loss of $1.4 million in the prior year, primarily due to reduced costs of revenue and improved product mix.

Operating expenses for the quarter were reported at $21.2 million, a substantial decrease from $427.6 million in the first quarter of 2025. This decline was largely attributed to a reduction in restructuring charges and a gain of $45.8 million from the disposal of assets related to the sale of certain intellectual property to Illumina Cambridge Limited. The operating loss narrowed to $8.4 million compared to a loss of $428.9 million in the same quarter last year. The net loss for the quarter was $8.3 million, significantly lower than the $426.1 million loss reported in the first quarter of 2025.

In terms of strategic developments, PacBio completed the asset sale to Illumina, which generated approximately $48.1 million in net cash proceeds. The company also entered into a license and settlement agreement with Personal Genomics of Taiwan, Inc., which includes a structured payment plan over the next few years. These transactions are part of PacBio's ongoing efforts to streamline operations and focus on its core sequencing technologies, particularly the HiFi long-read sequencing systems.

Operationally, PacBio reported a cash position of $276 million as of March 31, 2026, a slight decrease from $279.5 million at the end of 2025. The company continues to face challenges in the market, including funding constraints affecting instrument sales and longer sales cycles. However, it anticipates revenue growth in the latter half of 2026, driven by increased clinical adoption and the upcoming launch of new consumables. The company is also focused on expanding its product offerings and enhancing the capabilities of its existing platforms to capture a larger market share.

Looking ahead, PacBio aims to accelerate the adoption of its HiFi sequencing technology and expand its market presence through strategic initiatives. The company plans to invest in product innovation and enhance its data analytics capabilities to support advanced applications in genomics. Despite the current macroeconomic challenges, including inflation and supply chain pressures, PacBio remains optimistic about its growth prospects and the potential for significant revenue generation in the clinical sequencing market.